Showing results (461-470 of 566) with videos related to

Sort By:
Pageof 57
Arthritis & Rheumatology (Hoboken, N.J.)|July 24, 2018
Brief Report: How Do Patients With Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification CriteriaMarta Mosca, Karen H Costenbader, Sindhu R Johnson, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 24, 2022
Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD TrialEric L Matteson, Clive Kelly, Jörg H W Distler, et al.
Seminars in Arthritis and Rheumatism|January 6, 2026
Determining the best discriminatory physical functioning outcome measurement instrument for psoriatic arthritis trials: A meta-epidemiological studyYing-Ying Leung, Tobias Haugegaard, Tommy Kok Annfeldt, et al.
The Journal of Rheumatology|May 3, 2019
Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology TrialsLouise Klokker, Dorthe B Berthelsen, Thasia Woodworth, et al.
Seminars in Arthritis and Rheumatism|October 18, 2017
A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiativePil Højgaard, Louise Klokker, Ana-Maria Orbai, et al.
Arthritis Care & Research|September 28, 2019
Associations Between Classification Criteria Items in Systemic Lupus ErythematosusZahi Touma, Ricard Cervera, Ralph Brinks, et al.
Zeitschrift Fur Orthopadie Und Unfallchirurgie|May 29, 2024
Evidence-based and Patient-centered Indication for Knee Arthroplasty - Update of the GuidelineJörg Lützner, Stefanie Deckert, Toni Lange, et al.
The Journal of Rheumatology|May 3, 2017
Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working GroupAlexis Ogdie, Maarten de Wit, Kristina Callis Duffin, et al.
Annals of the Rheumatic Diseases|September 11, 2023
Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3)Peter C Taylor, Michael E Weinblatt, Iain B McInnes, et al.
The Journal of Rheumatology|August 4, 2004
Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trialJoel Kremer, Mark Genovese, Grant W Cannon, et al.
Pageof 57